NASDAQ:AXNX Axonics (AXNX) Stock Price, News & Analysis $70.24 +0.01 (+0.01%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Axonics Stock (NASDAQ:AXNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Axonics alerts:Sign Up Key Stats Today's Range$70.14▼$70.3750-Day Range$68.70▼$70.3552-Week Range$48.30▼$70.53Volume491,810 shsAverage Volume715,164 shsMarket Capitalization$3.58 billionP/E RatioN/ADividend YieldN/APrice Target$69.57Consensus RatingHold Company OverviewAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Axonics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks77th Percentile Overall ScoreAXNX MarketRank™: Axonics scored higher than 77% of companies evaluated by MarketBeat, and ranked 288th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingHold Consensus RatingAxonics has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 1 buy rating, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAxonics has only been the subject of 1 research reports in the past 90 days.Read more about Axonics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth262.50% Earnings GrowthEarnings for Axonics are expected to grow by 262.50% in the coming year, from $0.24 to $0.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics is -1,755.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics is -1,755.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics has a P/B Ratio of 5.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axonics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.15% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Axonics has recently decreased by 12.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxonics does not currently pay a dividend.Dividend GrowthAxonics does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-1.38 Percentage of Shares Shorted6.15% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Axonics has recently decreased by 12.78%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.40 News SentimentAxonics has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Axonics this week, compared to 3 articles on an average week.Search Interest1 people have searched for AXNX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Axonics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Axonics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $205,523.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of Axonics is held by insiders.Percentage Held by Institutions99.48% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axonics' insider trading history. Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXNX Stock News HeadlinesInsider Selling: Axonics, Inc. (NASDAQ:AXNX) CFO Sells 2,961 Shares of StockOctober 4, 2024 | insidertrades.comAxonics, Inc. (NASDAQ:AXNX) Given Consensus Recommendation of "Hold" by AnalystsOctober 21, 2024 | americanbankingnews.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 29, 2024 | Porter & Company (Ad)Piper Sandler Keeps Their Hold Rating on Axonics Modulation Technologies (AXNX)September 20, 2024 | markets.businessinsider.comAxonics defeats Medtronic lawsuit in spine-stimulation patent trialSeptember 19, 2024 | reuters.comJury Finds Axonics Did Not Infringe Any of Three Patents-in-SuitSeptember 18, 2024 | marketwatch.comAxonics Prevails in Patent Infringement Lawsuit with MedtronicSeptember 18, 2024 | businesswire.comAxonics Modulation Technologies Inc (AXNX)September 2, 2024 | investing.comSee More Headlines AXNX Stock Analysis - Frequently Asked Questions How have AXNX shares performed this year? Axonics' stock was trading at $62.23 on January 1st, 2024. Since then, AXNX stock has increased by 12.9% and is now trading at $70.24. View the best growth stocks for 2024 here. How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Thursday, August, 1st. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.03. The company's revenue for the quarter was up 23.3% compared to the same quarter last year. When did Axonics IPO? Axonics (AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. Who are Axonics' major shareholders? Axonics' top institutional investors include Kapitalo Investimentos Ltda (0.63%), Oak Ridge Investments LLC (0.16%), Creative Planning (0.01%) and SG Americas Securities LLC. Insiders that own company stock include Raymond W Cohen, John Woock, Rinda Sama, Kari Leigh Keese, Alfred J Ford Jr, Karen Noblett, Danny L Dearen, Jane E Kiernan and Esteban Lopez. View institutional ownership trends. How do I buy shares of Axonics? Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axonics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), NVIDIA (NVDA), TotalEnergies (TTE) and The RMR Group (RMR). Company Calendar Last Earnings8/01/2024Today10/29/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXNX CUSIPN/A CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$69.57 High Stock Price Target$71.00 Low Stock Price Target$63.00 Potential Upside/Downside-1.0%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E Ratio292.67 P/E GrowthN/ANet Income$-6,090,000.00 Net Margins-0.42% Pretax Margin0.50% Return on Equity-0.27% Return on Assets-0.24% Debt Debt-to-Equity RatioN/A Current Ratio8.96 Quick Ratio7.11 Sales & Book Value Annual Sales$408.81 million Price / Sales8.77 Cash Flow$0.13 per share Price / Cash Flow556.97 Book Value$12.59 per share Price / Book5.58Miscellaneous Outstanding Shares51,018,000Free Float50,172,000Market Cap$3.58 billion OptionableOptionable Beta0.82 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:AXNX) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axonics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.